Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)

PHASE3CompletedINTERVENTIONAL
Enrollment

683

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

November 30, 2010

Study Completion Date

May 31, 2011

Conditions
In Vitro Fertilization
Interventions
DRUG

Progesterone

25 mg, s.c., once à day

DRUG

Progesterone

90 mg, vaginally, once à day

Trial Locations (14)

1088

First Dept. Obstetric and Gynaecology, Semmelweiss University Faculty of Medicine, Budapest

4031

Universitätsfrauenklinik Basel, Basel

6924

IIRM SA, Sorengo

20122

Clinica Mangiagalli, Università di Milano, Milan

20132

Istituto Scientifico Universitario San Raffaele, Milan

23538

Klinik fur Frauenheilkunde und Geburthilfe - Universistät zu Lübeck, Lübeck

39031

Unità Ospedaliera di Ginecologia e Ostetricia, Ospedale Civico Brunico, Bruneck

41100

Azienda Ospedaliero-Sanitaria di Modena, Modena

56100

Ospedale Santa Chiara, Università degli studi di Pisa, Pisa

80131

Università degli Studi di Napoli 'Federico II, Naples

WS9 8LT

Midland Fertility Services, Aldridge

EC1A 7BE

St. Bartholomew's Hospital - Center for Reproductive Medicine, London

SE1 9RT

Guy's and St. Thomas' Hospital - Women's Health Department, London

SE1 9RY

The Bridge Center, London

Sponsors
All Listed Sponsors
lead

IBSA Institut Biochimique SA

INDUSTRY

NCT00827983 - Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF) | Biotech Hunter | Biotech Hunter